$QBIO Uttroside-B - Liver Cancer Chemotherapeutic We are

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
261
$QBIO Uttroside-B - Liver Cancer Chemotherapeutic

We are developing an innovative treatment for liver cancer, a disease indication that currently has a high unmet need. Currently, there are only two approved first-line therapies. We licensed and have advanced Uttroside-B, a new molecule that showed ten times the potency of the current standard of care in early pre-clinical investigation. Uttroside-B was discovered in the leaf of the Black Nightshade plant in India. As it is not feasible to use the plant as the source for a drug, we successfully synthesized the molecule thereby creating an exact replica of the naturally occurring chemical compound. We are now preparing to advance this into a pre-clinical program and have recently been awarded Orphan Drug designation. Manufacturing and scale-up of the drug for use in preclinical testing and IND application has begun. Pre-clinical testing is underway and early results are encouraging.

Corporate Strategic Goals

Our mission is to solve problems by accelerating the development of important therapies and availability of those therapies to patients. We believe we are creating value for our shareholders as we approach some milestones and catalysts. In particular we are very encouraged by the de-risking of the Mannin platform with significant non-dilutive funding to support the clinical program and potential for licensing opportunities in multiple therapeutic areas over the next 12 months. This along with the growth in the Strontium revenue and addition of potential products in the same vertical could provide meaningful revenue opportunities over the next 6 – 24 months.

The funding we have raised to date has allowed us to settle some outstanding payables, prepare for an uplisting on a senior exchange and to continue developing our current assets. The uplisting will coincide with a proposed capital raise that, in the minimum, will satisfy our next 12 month capital needs. Our priority is to continue to support and expand a contract sales force for Strontium-89 in commercial and federal settings and possibly increase the product offering in this nuclear medicine vertical. We will also focus on advancing our rare disease portfolio in liver cancer, and leveraging the now almost $20,000,000 in committed non-dilutive government funding for the Mannin platform of vascular therapeutics for Acute Respiratory Distress Syndrome for COVID-19 patients as well as Glaucoma, Kidney diseases and others.

We believe our current valuation is not reflective of the opportunity within our pipeline. The pandemic environment has certainly made our job much harder, but that does not allow us to avoid blame for some missteps along the way. We have learned much about our business and the 'new normal' in which we have to operate and what we think will make our current opportunities more valuable to the market. We continue to believe that we have created a valuable and exciting company and expect to see that translate over the next 12 months as we approach several significant milestones. We are resilient and better prepared for our future than ever before.

About Q BioMed Inc.

Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need?.

Please visit http://www.QBioMed.com and sign up for regular updates.
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 75

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Africa Tech Awards Put Infrastructure Back in Focus

Updated Category News Views 97

Twelve trophies in Cape Town tell a more useful story than most glossy technology forecasts ever manage to. The Africa Tech Festival Awards 2026, announced on November 19 during the event's 29th annual gathering, cut across connectivity, telecoms, AI, cybersecurity, data centres, cloud, fintech, startups and enterprise transformation. That breadth matters. Africa's...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 48

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 148

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 78

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 53

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 172

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 134

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 91

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Trends: The Effects of Inflation on Stock Futures

Updated Category News Views 87

Understanding Stock Market Movements Amid Inflation The stock market is always changing, and the way inflation data interacts with labor statistics often shapes its future direction. Recently, U.S. stock futures saw a slight uptick as investors digested fresh figures, weighing how these will influence upcoming decisions regarding interest rate cuts. Current Market...

Continue Reading
SMBC Nikko America Achieves Primary Dealer Status with Fed

Updated Category News Views 557

SMBC Nikko America Achieves Primary Dealer Designation SMBC Nikko Securities America, Inc., commonly referred to as SMBC Nikko America, has recently been honored with the designation of primary dealer by the Federal Reserve Bank of New York. This prestigious status is not only a recognition of the firm’s robust capabilities but also signals significant opportunities for...

Continue Reading
USD and Global Currency Trends Amid Upcoming Economic Events

Updated Category News Views 272

Currency Market Insights for the Upcoming Week As economic indicators and central bank policies loom large, the focus shifts to the financial markets where currencies react to evolving data. The US dollar has shown resilience recently, making a notable comeback. This rebound is attributed to a combination of safe haven flows and exceptionally positive data releases. Fed...

Continue Reading
Transforming $100 into Wealth: American Tower's Success Story

Updated Category News Views 152

The Wealth Generated by American Tower's Growth American Tower (NYSE: AMT) has exhibited exceptional performance over the past two decades, consistently outshining the market with a remarkable annual return of 10.05%. As of now, this powerhouse company boasts a market capitalization of approximately $83 billion, signaling its robust position in the telecommunications...

Continue Reading
Calcea: The Future of Calcium with Plant-Based Solutions

Updated Category News Views 258

Revolutionizing Calcium Supplements with Calcea Calcium is recognized as the most abundant mineral in the human body, yet many of the supplements available today are derived from ground-up rocks – materials that aren't aligned with the nutritional needs of the human body. With consumers increasingly prioritizing cleaner and more effective supplements, the calcium market...

Continue Reading